Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Neurobiol. 2016 Feb 3;54(2):1392–1403. doi: 10.1007/s12035-016-9746-0

Fig. 2.

Fig. 2

Validation of miR-196a expression in human skin fibroblasts (a) and human brain samples (b) by qRT-PCR. miR-196a expression was validated in human skin fibroblasts and human brain samples (from equivalent brain regions) using Qiagen miScript primer assays by qRT-PCR. The values were normalized to SNORD61 and presented as fold change. As represented by figure, miR-196a expression was downregulated in cALD fibroblasts and brain samples and upregulated in AMN fibroblasts and brain samples. B3 is brain sample from AMN that subsequently developed CNS disease. Downregulation of miR-196a expression in brain sample B3 indicates of cerebral involvement. Thirty-five percent of AMN patients develop cerebral involvement